A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

PURPOSE: Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy. METHODS: As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 dose-escalation design), we determined the maximum tolerated dose (MTD) of afatini...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Mary E. R., Sarker, Debashis, Bhosle, Jaishree, Thillai, Kiruthikah, Yap, Timothy A., Uttenreuther-Fischer, Martina, Pemberton, Karine, Jin, Xidong, Wiebe, Sabrina, de Bono, Johann, Spicer, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182763/
https://www.ncbi.nlm.nih.gov/pubmed/30088048
http://dx.doi.org/10.1007/s00280-018-3661-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182763/
https://www.ncbi.nlm.nih.gov/pubmed/30088048
http://dx.doi.org/10.1007/s00280-018-3661-1

Ejemplares similares